Karen S Pieper

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events
    Karen S Pieper
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 157:1097-105. 2009
  2. ncbi request reprint Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods
    Karen S Pieper
    Duke Clinical Research Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27715, USA
    Circulation 109:641-6. 2004
  3. doi request reprint Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 163:797-803. 2012
  4. doi request reprint Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease
    Svati H Shah
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 163:844-850.e1. 2012
  5. doi request reprint Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:320-6. 2012
  6. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
  7. doi request reprint Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 124:48-57. 2011
  8. ncbi request reprint A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 47:809-16. 2006
  9. doi request reprint The impact of postrandomization crossover of therapy in acute coronary syndromes care
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:211-9. 2011
  10. ncbi request reprint Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Interv Cardiol 20:299-306. 2007

Detail Information

Publications55

  1. doi request reprint Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events
    Karen S Pieper
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 157:1097-105. 2009
    ..The aim of this study was to explore the impact of modeling techniques on the risk model when generating predictions...
  2. ncbi request reprint Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods
    Karen S Pieper
    Duke Clinical Research Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27715, USA
    Circulation 109:641-6. 2004
    ..The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials...
  3. doi request reprint Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 163:797-803. 2012
    ..Information on practice patterns and outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary interventions (PCIs) in Canada vs United States is limited...
  4. doi request reprint Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease
    Svati H Shah
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 163:844-850.e1. 2012
    ..Cardiovascular risk models remain incomplete. Small-molecule metabolites may reflect underlying disease and, as such, serve as novel biomarkers of cardiovascular risk...
  5. doi request reprint Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:320-6. 2012
    ..These data highlight the importance of understanding factors associated with gender-related differences in bleeding and represent an opportunity for improving outcomes of women and men with fibrinolytic-treated STEMI...
  6. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
    ..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...
  7. doi request reprint Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 124:48-57. 2011
    ....
  8. ncbi request reprint A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 47:809-16. 2006
    ..The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes...
  9. doi request reprint The impact of postrandomization crossover of therapy in acute coronary syndromes care
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:211-9. 2011
    ..Using SYNERGY as an example, we demonstrate the difficulty of evaluating the effect of postrandomization events in clinical trials and discuss possible methodology...
  10. ncbi request reprint Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Interv Cardiol 20:299-306. 2007
    ..Adverse events occur following non-ST elevation acute coronary syndromes (NSTE ACS). However, the timing of these events in relation to index event is less clear...
  11. doi request reprint Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease
    Mark Y Chan
    Duke Clinical Research Institute, Durham, North Carolina, USA
    JACC Cardiovasc Interv 1:369-78. 2008
    ..We sought to characterize the utilization and impact of a conservative medical management strategy for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and significant coronary artery disease on early angiography...
  12. pmc Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 23:310-6. 2008
    ..Despite advances in pharmacologic therapy and invasive management strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), these patients still suffer substantial morbidity and mortality...
  13. ncbi request reprint Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC, USA
    Am J Med 119:70.e1-8. 2006
    ..Accordingly, the current study examines the relationship of African American race to patient-related clinical factors, angiographic findings, and clinical events...
  14. ncbi request reprint The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA, and Greenlane Cardiovascular Service, Auckland City Hospital, New Zealand
    Eur Heart J 28:415-24. 2007
    ..However, the relative prognostic importance of these measures over other baseline variables is less known...
  15. pmc Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes
    Adriano A M Truffa
    Duke Clinical Research Institute and the Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705, USA
    JACC Cardiovasc Interv 5:769-76. 2012
    ..We also assessed the association between serious infections and 90-day death or death/myocardial infarction (MI)...
  16. ncbi request reprint Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:315-21. 2007
    ..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
  17. doi request reprint Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Box 17969, Durham, NC 27715, USA
    Eur Heart J 29:880-7. 2008
    ....
  18. ncbi request reprint Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1200-6. 2005
    ..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
  19. ncbi request reprint Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock
    Rajendra H Mehta
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:793-6. 2007
    ..This information may help physicians in deciding treatment options for patients with cardiogenic shock and counseling them about their risks...
  20. doi request reprint International variation in and factors associated with hospital readmission after myocardial infarction
    Robb D Kociol
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    JAMA 307:66-74. 2012
    ..Recently, 30-day readmission rates have been proposed as a metric for care of patients with STEMI. However, international rates and predictors of 30-day readmission after STEMI have not been studied...
  21. ncbi request reprint Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Card Fail 12:684-8. 2006
    ..Recent data suggest that differences in response to therapy and survival exist between African Americans and Caucasians with heart failure. Whether these differences exist in acute decompensated heart failure (ADHF) is uncertain...
  22. doi request reprint Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 161:782-9. 2011
    ....
  23. doi request reprint Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 32:242-66. 2011
    ..This paper summarizes the symposium proceedings...
  24. doi request reprint Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 124:544-54. 2011
    ..045), with less effect of ticagrelor in North America than in the rest of the world...
  25. ncbi request reprint Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:1371-5. 2005
    ..962 (95% CI 0.896 to 1.033). These data indicate that height-related differences in 30-day mortality are explained in large part by height-related differences in patients' clinical characteristics...
  26. ncbi request reprint Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
    JAMA 293:1746-50. 2005
    ..Incorrect dosing of alteplase has been associated with worse clinical outcomes in patients. However, patients at high risk of adverse events are more prone to dosing errors, thus confounding this relationship...
  27. doi request reprint The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction
    Sean van Diepen
    Division of Cardiology and Critical Care, University of Alberta, Edmonton, Alberta, Canada
    Crit Care Med 41:2080-7. 2013
    ..To assess whether systemic inflammatory response syndrome is associated with morbidity and mortality in ST-elevation myocardial infarction...
  28. doi request reprint Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
    Richard C Becker
    Duke Clinical Research Institute, Durham, NC, USA
    Lancet 373:919-28. 2009
    ..We therefore assessed the tolerability and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist...
  29. doi request reprint Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY)
    Jason P Linefsky
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 104:1330-5. 2009
    ..More MI outcomes were identified by the core laboratory, and patients with MI as defined by core laboratory data had lower 1-year survival, making these events potentially clinically important...
  30. doi request reprint Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    JAMA 301:1779-89. 2009
    ....
  31. ncbi request reprint Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, North Carolina Department of Medicine, Stanford University, Stanford, California
    Clin Cardiol 37:337-42. 2014
    ..We sought to compare ischemic and bleeding outcomes in hospitalized patients enrolled in clinical trials of non-ST-elevation acute coronary syndrome (ACS) with patients enrolled in outpatient trials of CSA...
  32. doi request reprint Representation of women in randomized clinical trials of cardiovascular disease prevention
    Chiara Melloni
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 3:135-42. 2010
    ....
  33. ncbi request reprint Predictors of hospital mortality in the global registry of acute coronary events
    Christopher B Granger
    Division of Cardiology, University Medical Center, Durham, NC, USA
    Arch Intern Med 163:2345-53. 2003
    ..Management of acute coronary syndromes (ACS) should be guided by an estimate of patient risk...
  34. doi request reprint Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial
    S Michael Gharacholou
    Division of Cardiology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Arch Intern Med 171:559-67. 2011
    ....
  35. ncbi request reprint Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)
    Donal N Reddan
    Division of Nephrology and Duke Institute for Renal Outcomes and Health Policy, Durham, North Carolina 27705, USA
    Am J Cardiol 91:17-21. 2003
    ..94). An accompanying increase in bleeding risk also was not apparent with lower CrCl. The treatment effect of eptifibatide is realized regardless of renal function and trends toward being greater in patients with mild renal impairment...
  36. ncbi request reprint Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 94:926-9. 2004
    ....
  37. ncbi request reprint Mobile cardiac catheterization laboratories increase use of cardiac care in women and African Americans
    Michael H Sketch
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 154:532-8. 2007
    ..We sought to determine whether mobile cardiac catheterization laboratories may increase the use of catheterization among women and minorities by bringing the technology to remote communities...
  38. ncbi request reprint Can one assess whether missing data are missing at random in medical studies?
    Richard F Potthoff
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Stat Methods Med Res 15:213-34. 2006
    ..If MAR+ is found to fail for a study whose data have already been gathered, extra caution may need to be exercised in the interpretation of the results...
  39. doi request reprint Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 139:120-9.e18. 2010
    ..We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR...
  40. ncbi request reprint A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry
    Kim A Eagle
    Department of Internal Medicine, University of Michigan Health System, Ann Arbor, USA
    JAMA 291:2727-33. 2004
    ..Accurate estimation of risk for untoward outcomes after patients have been hospitalized for an acute coronary syndrome (ACS) may help clinicians guide the type and intensity of therapy...
  41. pmc Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)
    Keith A A Fox
    Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh EH16 4SB
    BMJ 333:1091. 2006
    ..To develop a clinical risk prediction tool for estimating the cumulative six month risk of death and death or myocardial infarction to facilitate triage and management of patients with acute coronary syndrome...
  42. ncbi request reprint Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes
    Jassim Al Suwaidi
    Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circulation 106:974-80. 2002
    ..Outcomes in patients with mild to moderate renal function (RF) abnormalities presenting with acute coronary syndromes (ACS) are not well defined...
  43. ncbi request reprint Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
    Debabrata Mukherjee
    University of Michigan Health System, Ann Arbor, Mich, USA
    Am Heart J 144:995-1002. 2002
    ..Minimal data are available on LMWH combined with platelet glycoprotein (GP) IIb/IIIa inhibitors...
  44. ncbi request reprint Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience
    Warren J Cantor
    St Michael s Hospital, Division of Cardiology, 30 Bond Street, Toronto, Ontario, Canada, M44 1W8
    J Invasive Cardiol 16:475-81. 2004
    ..Post-procedural MI is often not detected until greater than or equal to 12 hours after PCI. Treatment with a glycoprotein IIb/IIIa inhibitor is the only modifiable parameter that reduces the risk for early ischemic complications...
  45. ncbi request reprint A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting
    Mina Madan
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Can J Cardiol 20:1343-9. 2004
    ..Few data are available comparing PCI outcomes between the two countries in the era of coronary stenting and adjunctive glycoprotein IIb/IIIa inhibition...
  46. ncbi request reprint Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome
    Andrew T Yan
    Terrence Donnelly Heart Centre, Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Am Heart J 148:1020-7. 2004
    ..The purpose of this study was to validate and compare a modified international clinical trial and a registry-based risk model in a contemporary, less selected ACS population...
  47. ncbi request reprint Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials
    Mauricio G Cohen
    Division of Cardiology, University of North Carolina at Chapel Hill, 130 Mason Farm Road, CB 7075, Bioinformatics Building Suite 4128, Chapel Hill, NC 27599, USA
    Am J Med 118:482-8. 2005
    ..To correlate pulmonary artery catheterization (PAC) use and 30-day outcomes and to characterize the use of pulmonary artery catheters among patients with acute coronary syndromes (ACS)...
  48. ncbi request reprint Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes
    Stefano Savonitto
    Dipartimento Cardio Toraco Vascolare, A De Gasperis, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
    Eur Heart J 26:2106-13. 2005
    ..Although the presence of ischaemic ECG changes on admission has been shown to predict outcome, the relationship between the extent of ECG changes and the risk of cardiac events is still ill defined...
  49. ncbi request reprint Predictors of mortality and morbidity in patients with chronic heart failure
    Stuart J Pocock
    Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Eur Heart J 27:65-75. 2006
    ..We aimed to develop prognostic models for patients with chronic heart failure (CHF)...
  50. ncbi request reprint Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial
    Joseph A Puma
    New York Methodist Hospital Cornell Heart Center, Brooklyn New York 11215, USA
    J Am Coll Cardiol 47:715-8. 2006
    ..In order to determine a differential benefit from treatment, we compared the long-term outcome of high-risk versus low-risk patients and evaluated survival free from death or myocardial infarction at one year...
  51. ncbi request reprint Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 152:1042-50. 2006
    ..The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding...
  52. ncbi request reprint Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial
    Jean Pierre Dery
    Department of Cardiology, The Quebec Heart and Lung Institute, Quebec, Canada
    Catheter Cardiovasc Interv 70:43-50. 2007
    ..This analysis sought to investigate the complementary effect of thienopyridine pretreatment and platelet glycoprotein (GP) IIb/IIIa integrin blockade in coronary stent intervention...
  53. ncbi request reprint Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience
    Kent Stephenson
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Heart Rhythm 4:308-13. 2007
    ....
  54. doi request reprint Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy
    Derek P Chew
    Flinders Medical Centre, South Australia, Adelaide, Australia
    Am Heart J 155:239-44. 2008
    ..We explored the clinical outcomes among high-risk patients undergoing CABG and the impact of modern pharmacology...
  55. ncbi request reprint The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes
    Stefano Savonitto
    Department of Cardiology, Niguarda Hospital, Milan, Italy
    J Am Coll Cardiol 39:22-9. 2002
    ..The study investigated the relationship among creatine kinase (CK) elevations, clinical characteristics and cardiac events across the whole spectrum of acute coronary syndromes (ACS)...